Since 2006, HKU/QMH has been accredited by the CFDA for conducting clinical drug trials in six clinical specialties (including cardiology, endocrinology & metabolism, haematology & bone marrow transplantation, hepatobiliary & pancreatic surgery/liver transplantation, obstetrics & gynaecology, and respiratory medicine). With the new accreditation for the HKU Phase 1 Clinical Trials Centre and seven additional clinical specialties in July 2016 (including clinical immunology, gastroenterology and hepatology, nephrology, neurology, oncology, orthopaedics & traumatology, and paediatrics & adolescent medicine), HKU/QMH now is accredited by the CFDA in a total of 14 areas.
The accreditation for the HKU Phase 1 Clinical Trials Centre is of exceptional importance as there was no official accreditation for any phase 1 centre in China.
|CFDA-accredited Clinical Specialties/Areas in QMH/HKU (14 areas)|
|Endocrinology & Metabolism|
|Gastroenterology & Hepatology|
|Haematology & Bone Marrow Transplantation|
|Hepatobiliary & Pancreatic Surgery and Liver Transplantation|
|HKU Phase 1 Clinical Trials Centre|
|Obstetrics & Gynaecology|
|Orthopaedics & Traumatology|
|Paediatrics & Adolescent Medicine|